What is the P/E ratio of Chiome Bioscience 2025?
The P/E ratio cannot be calculated for Chiome Bioscience at the moment.
Access the world's leading financial data and tools
Subscribe for $2 
Overview
Profile
Chiome Bioscience stock stock price, forecast, news, chart, split, dividend and analysis Chiome Bioscience ariva, Chiome Bioscience onvista, Chiome Bioscience finanzen.net, Chiome Bioscience aktienfinder, Chiome Bioscience marketscreener, Chiome Bioscience marketwatch, Chiome Bioscience bloomberg, Chiome Bioscience handelsblatt, Chiome Bioscience wiwo, Chiome Bioscience forum
4583.T
JP3205350006
Price
Price
169.00
Today +/-
-0.01
Today %
-0.59 %
Ticker4583.T
ISINJP3205350006
Chiome Bioscience stock price
%
Weekly
Details
Price
ⓘOverview
The Quote Chart provides detailed and dynamic insights into the Chiome Bioscience stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.
Intraday Feature
The intraday feature provides real-time data, allowing investors to view the Chiome Bioscience stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.
Total Return and Relative Price Change
View the total return of the Chiome Bioscience stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.
Interpretation and Investment
Utilize the comprehensive data presented in the Quote Chart to analyze Chiome Bioscience's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.
Chiome Bioscience Stock Price History
| Date | Chiome Bioscience Price |
|---|---|
| 2/25/2025 | 169.00 undefined |
| 2/21/2025 | 170.00 undefined |
| 2/20/2025 | 176.00 undefined |
| 2/19/2025 | 184.00 undefined |
| 2/18/2025 | 195.00 undefined |
| 2/17/2025 | 205.00 undefined |
| 2/14/2025 | 211.00 undefined |
| 2/13/2025 | 253.00 undefined |
| 2/12/2025 | 246.00 undefined |
| 2/10/2025 | 250.00 undefined |
| 2/7/2025 | 258.00 undefined |
| 2/6/2025 | 241.00 undefined |
| 2/5/2025 | 248.00 undefined |
| 2/4/2025 | 249.00 undefined |
| 2/3/2025 | 248.00 undefined |
| 1/31/2025 | 249.00 undefined |
| 1/30/2025 | 255.00 undefined |
| 1/29/2025 | 237.00 undefined |
| 1/28/2025 | 240.00 undefined |
Chiome Bioscience Revenue, EBIT, Net Income JP3205350006 ·
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Chiome Bioscience, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Chiome Bioscience from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Chiome Bioscience’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Chiome Bioscience. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Chiome Bioscience’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Chiome Bioscience’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Chiome Bioscience’s growth potential.
Chiome Bioscience Revenue, EBIT and net profit per share
| Date | Chiome Bioscience Revenue | Chiome Bioscience EBIT | Chiome Bioscience Net Income |
|---|---|---|---|
| 2023 | 682.46 M undefined | -1.21 B undefined | -1.22 B undefined |
| 2022 | 630.82 M undefined | -1.26 B undefined | -1.24 B undefined |
| 2021 | 712.93 M undefined | -1.33 B undefined | -1.48 B undefined |
| 2020 | 480.85 M undefined | -1.28 B undefined | -1.29 B undefined |
| 2019 | 447.58 M undefined | -1.4 B undefined | -1.4 B undefined |
| 2018 | 212.85 M undefined | -1.54 B undefined | -1.53 B undefined |
| 2017 | 259.9 M undefined | -887.87 M undefined | -882.57 M undefined |
| 2016 | 252.22 M undefined | -1.04 B undefined | -1.49 B undefined |
| 2015 | 280.11 M undefined | -1.27 B undefined | -1.28 B undefined |
| 2014 | 277.8 M undefined | -865.6 M undefined | -863.3 M undefined |
| 2013 | 435 M undefined | -708.9 M undefined | -757.6 M undefined |
| 2012 | 324.1 M undefined | -413.2 M undefined | -426.9 M undefined |
| 2011 | 633.2 M undefined | -7.3 M undefined | -44.4 M undefined |
| 2010 | 463.2 M undefined | -231.2 M undefined | -180.2 M undefined |
| 2009 | 380.8 M undefined | -201.5 M undefined | -164.4 M undefined |
| 2008 | 161.8 M undefined | -213 M undefined | -204.6 M undefined |
| 2007 | 34.2 M undefined | -248.9 M undefined | -227.3 M undefined |
| 2006 | 13.9 M undefined | -193.8 M undefined | -141.9 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2006 | 13.9 M JPY | -193.8 M JPY | -141.9 M JPY |
| 2007 | 34.2 M JPY | -248.9 M JPY | -227.3 M JPY |
| 2008 | 161.8 M JPY | -213 M JPY | -204.6 M JPY |
| 2009 | 380.8 M JPY | -201.5 M JPY | -164.4 M JPY |
| 2010 | 463.2 M JPY | -231.2 M JPY | -180.2 M JPY |
| 2011 | 633.2 M JPY | -7.3 M JPY | -44.4 M JPY |
| 2012 | 324.1 M JPY | -413.2 M JPY | -426.9 M JPY |
| 2013 | 435 M JPY | -708.9 M JPY | -757.6 M JPY |
| 2014 | 277.8 M JPY | -865.6 M JPY | -863.3 M JPY |
| 2015 | 280.11 M JPY | -1.27 B JPY | -1.28 B JPY |
| 2016 | 252.22 M JPY | -1.04 B JPY | -1.49 B JPY |
| 2017 | 259.9 M JPY | -887.87 M JPY | -882.57 M JPY |
| 2018 | 212.85 M JPY | -1.54 B JPY | -1.53 B JPY |
| 2019 | 447.58 M JPY | -1.4 B JPY | -1.4 B JPY |
| 2020 | 480.85 M JPY | -1.28 B JPY | -1.29 B JPY |
| 2021 | 712.93 M JPY | -1.33 B JPY | -1.48 B JPY |
| 2022 | 630.82 M JPY | -1.26 B JPY | -1.24 B JPY |
| 2023 | 682.46 M JPY | -1.21 B JPY | -1.22 B JPY |
Chiome Bioscience Income Statement, Balance Sheet, Cash Flow Statement
Simple
Expanded
Income Statement
Balance Sheet
Cashflow
| 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13 | 34 | 161 | 380 | 463 | 633 | 324 | 435 | 277 | 280 | 252 | 259 | 212 | 447 | 480 | 712 | 630 | 682 |
| - | 161.54 | 373.53 | 136.02 | 21.84 | 36.72 | -48.82 | 34.26 | -36.32 | 1.08 | -10.00 | 2.78 | -18.15 | 110.85 | 7.38 | 48.33 | -11.52 | 8.25 |
| 30.77 | 35.29 | 42.24 | 57.37 | 57.02 | 66.19 | 62.96 | 60.00 | 67.87 | 50.71 | 45.24 | 67.18 | 52.36 | 63.53 | 51.04 | 59.27 | 55.24 | 58.36 |
| 4 | 12 | 68 | 218 | 264 | 419 | 204 | 261 | 188 | 142 | 114 | 174 | 111 | 284 | 245 | 422 | 348 | 398 |
| -141 | -227 | -204 | -164 | -180 | -44 | -426 | -757 | -863 | -1,282 | -1,491 | -882 | -1,533 | -1,403 | -1,293 | -1,479 | -1,242 | -1,220 |
| - | 60.99 | -10.13 | -19.61 | 9.76 | -75.56 | 868.18 | 77.70 | 14.00 | 48.55 | 16.30 | -40.85 | 73.81 | -8.48 | -7.84 | 14.39 | -16.02 | -1.77 |
| 16.4 | 16.4 | 16.4 | 16.4 | 16.4 | 14.7 | 16.8 | 19.1 | 20.4 | 22 | 22.63 | 26.36 | 26.78 | 31.47 | 35.88 | 40.28 | 43.98 | 49.55 |
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Details
Keystats
ⓘRevenue and Growth
The Chiome Bioscience Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.
Gross Margin
The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.
EBIT and EBIT Margin
EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.
Income and Growth
Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.
Shares Outstanding
Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.
Interpreting Year to Year Comparison
Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.
Expectations and Predictions
Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Chiome Bioscience is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.
Chiome Bioscience stock margins JP3205350006 ·
The Chiome Bioscience margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Chiome Bioscience. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Chiome Bioscience.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Chiome Bioscience's sales revenue. A higher gross margin percentage indicates that the Chiome Bioscience retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Chiome Bioscience's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Chiome Bioscience's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Chiome Bioscience's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Chiome Bioscience. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Chiome Bioscience's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Chiome Bioscience Margin History
| Chiome Bioscience Gross margin | Chiome Bioscience Profit margin | Chiome Bioscience EBIT margin | Chiome Bioscience Profit margin |
|---|---|---|---|
| 2023 | 58.41 % | -176.59 % | -178.77 % |
| 2022 | 55.3 % | -199.53 % | -197.03 % |
| 2021 | 59.26 % | -187.16 % | -207.58 % |
| 2020 | 51.01 % | -266.95 % | -269.06 % |
| 2019 | 63.6 % | -313.23 % | -313.65 % |
| 2018 | 52.28 % | -723.1 % | -720.46 % |
| 2017 | 67.11 % | -341.63 % | -339.59 % |
| 2016 | 45.36 % | -413.28 % | -591.23 % |
| 2015 | 50.71 % | -453.36 % | -457.93 % |
| 2014 | 67.93 % | -311.59 % | -310.76 % |
| 2013 | 60 % | -162.97 % | -174.16 % |
| 2012 | 63.16 % | -127.49 % | -131.72 % |
| 2011 | 66.3 % | -1.15 % | -7.01 % |
| 2010 | 57.08 % | -49.91 % | -38.9 % |
| 2009 | 57.43 % | -52.91 % | -43.17 % |
| 2008 | 42.09 % | -131.64 % | -126.45 % |
| 2007 | 36.84 % | -727.78 % | -664.62 % |
| 2006 | 33.81 % | -1,394.24 % | -1,020.86 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2006 | 33.81 % | -1,394.24 % | -1,020.86 % |
| 2007 | 36.84 % | -727.78 % | -664.62 % |
| 2008 | 42.09 % | -131.64 % | -126.45 % |
| 2009 | 57.43 % | -52.91 % | -43.17 % |
| 2010 | 57.08 % | -49.91 % | -38.9 % |
| 2011 | 66.3 % | -1.15 % | -7.01 % |
| 2012 | 63.16 % | -127.49 % | -131.72 % |
| 2013 | 60 % | -162.97 % | -174.16 % |
| 2014 | 67.93 % | -311.59 % | -310.76 % |
| 2015 | 50.71 % | -453.36 % | -457.93 % |
| 2016 | 45.36 % | -413.28 % | -591.23 % |
| 2017 | 67.11 % | -341.63 % | -339.59 % |
| 2018 | 52.28 % | -723.1 % | -720.46 % |
| 2019 | 63.6 % | -313.23 % | -313.65 % |
| 2020 | 51.01 % | -266.95 % | -269.06 % |
| 2021 | 59.26 % | -187.16 % | -207.58 % |
| 2022 | 55.3 % | -199.53 % | -197.03 % |
| 2023 | 58.41 % | -176.59 % | -178.77 % |
Chiome Bioscience Stock Sales Revenue, EBIT, Earnings per Share JP3205350006 ·
The Chiome Bioscience earnings per share therefore indicates how much revenue Chiome Bioscience has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
3 years
5 years
10 years
25 Years
Max
Sales per Share
EBIT per share
Earnings per Share
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Chiome Bioscience earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Chiome Bioscience's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Chiome Bioscience’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Chiome Bioscience's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
Chiome Bioscience Revenue, EBIT and net profit per share
| Date | Chiome Bioscience Sales per Share | Chiome Bioscience EBIT per share | Chiome Bioscience Earnings per Share |
|---|---|---|---|
| 2023 | 13.77 undefined | -24.32 undefined | -24.62 undefined |
| 2022 | 14.34 undefined | -28.62 undefined | -28.26 undefined |
| 2021 | 17.7 undefined | -33.13 undefined | -36.74 undefined |
| 2020 | 13.4 undefined | -35.78 undefined | -36.06 undefined |
| 2019 | 14.22 undefined | -44.55 undefined | -44.61 undefined |
| 2018 | 7.95 undefined | -57.47 undefined | -57.26 undefined |
| 2017 | 9.86 undefined | -33.68 undefined | -33.48 undefined |
| 2016 | 11.15 undefined | -46.07 undefined | -65.91 undefined |
| 2015 | 12.73 undefined | -57.71 undefined | -58.29 undefined |
| 2014 | 13.62 undefined | -42.43 undefined | -42.32 undefined |
| 2013 | 22.77 undefined | -37.12 undefined | -39.66 undefined |
| 2012 | 19.29 undefined | -24.6 undefined | -25.41 undefined |
| 2011 | 43.07 undefined | -0.5 undefined | -3.02 undefined |
| 2010 | 28.24 undefined | -14.1 undefined | -10.99 undefined |
| 2009 | 23.22 undefined | -12.29 undefined | -10.02 undefined |
| 2008 | 9.87 undefined | -12.99 undefined | -12.48 undefined |
| 2007 | 2.09 undefined | -15.18 undefined | -13.86 undefined |
| 2006 | 0.85 undefined | -11.82 undefined | -8.65 undefined |
| Sales per Share | EBIT per share | Earnings per Share | |
|---|---|---|---|
| 2006 | 0.85 JPY | -11.82 JPY | -8.65 JPY |
| 2007 | 2.09 JPY | -15.18 JPY | -13.86 JPY |
| 2008 | 9.87 JPY | -12.99 JPY | -12.48 JPY |
| 2009 | 23.22 JPY | -12.29 JPY | -10.02 JPY |
| 2010 | 28.24 JPY | -14.1 JPY | -10.99 JPY |
| 2011 | 43.07 JPY | -0.5 JPY | -3.02 JPY |
| 2012 | 19.29 JPY | -24.6 JPY | -25.41 JPY |
| 2013 | 22.77 JPY | -37.12 JPY | -39.66 JPY |
| 2014 | 13.62 JPY | -42.43 JPY | -42.32 JPY |
| 2015 | 12.73 JPY | -57.71 JPY | -58.29 JPY |
| 2016 | 11.15 JPY | -46.07 JPY | -65.91 JPY |
| 2017 | 9.86 JPY | -33.68 JPY | -33.48 JPY |
| 2018 | 7.95 JPY | -57.47 JPY | -57.26 JPY |
| 2019 | 14.22 JPY | -44.55 JPY | -44.61 JPY |
| 2020 | 13.4 JPY | -35.78 JPY | -36.06 JPY |
| 2021 | 17.7 JPY | -33.13 JPY | -36.74 JPY |
| 2022 | 14.34 JPY | -28.62 JPY | -28.26 JPY |
| 2023 | 13.77 JPY | -24.32 JPY | -24.62 JPY |
Chiome Bioscience business model
Chiome Bioscience is one of the most popular companies on Eulerpool.com.
Chiome Bioscience Eulerpool Fair Value
Details
Fair Value
ⓘUnderstanding Fair Value
The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.
Income-Based Fair Value
This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.
Example 2022
Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)
Revenue-Based Fair Value
It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.
Example 2022
Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)
Dividend-Based Fair Value
This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.
Example 2022
Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)
Expectations and Forecasts
Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.
Comparative Analysis
Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.
Chiome Bioscience historical P/E ratio, EBIT multiple, and P/S ratio
Chiome Bioscience shares outstanding JP3205350006 ·
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Chiome Bioscience earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Chiome Bioscience's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Chiome Bioscience’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Chiome Bioscience's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2006 | 16.4 M Aktien |
| 2007 | 16.4 M Aktien |
| 2008 | 16.4 M Aktien |
| 2009 | 16.4 M Aktien |
| 2010 | 16.4 M Aktien |
| 2011 | 14.7 M Aktien |
| 2012 | 16.8 M Aktien |
| 2013 | 19.1 M Aktien |
| 2014 | 20.4 M Aktien |
| 2015 | 22 M Aktien |
| 2016 | 22.63 M Aktien |
| 2017 | 26.36 M Aktien |
| 2018 | 26.78 M Aktien |
| 2019 | 31.47 M Aktien |
| 2020 | 35.88 M Aktien |
| 2021 | 40.28 M Aktien |
| 2022 | 43.98 M Aktien |
| 2023 | 49.55 M Aktien |
Chiome Bioscience stock splits
In Chiome Bioscience's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Chiome Bioscience.
Chiome Bioscience shareholders
% | Name | Stocks | Change | Date |
|---|---|---|---|---|
| 2.13016 % | Watanabe (Kenji) | 1,450,000 | 450,000 | 6/30/2024 |
| 1.47422 % | Ehira (Fumishige) | 1,003,500 | 1,003,500 | 6/30/2024 |
| 1.46731 % | Ueda Yagi Tanshi Co., Ltd. | 998,800 | 0 | 6/30/2024 |
| 1.41428 % | Ota (Kunihiro) | 962,700 | 0 | 6/30/2024 |
| 1.02968 % | Japan Securities Finance Co Ltd | 700,900 | 700,900 | 6/30/2024 |
| 1.02835 % | Yoshimura (Koji) | 700,000 | 100,000 | 6/30/2024 |
| 0.93933 % | Growth Capital KK | 639,400 | 0 | 10/22/2024 |
| 0.81049 % | Hirata (Shigekazu) | 551,700 | 96,700 | 6/30/2024 |
| 0.75951 % | Iisaku (Tetsuo) | 517,000 | 20,000 | 6/30/2024 |
| 0.64639 % | Yamato (Fukutaro) | 440,000 | 40,000 | 6/30/2024 |
1
2
Chiome Bioscience Supply Chain
| Name | Relationship | Two-week correlation | One-month correlation | Three-Month Correlation | Six-Month Correlation | One Year Correlation | Two-Year Correlation |
|---|---|---|---|---|---|---|---|
| SupplierCustomer | 0,71 | 0,91 | 0,78 | 0,22 | 0,69 | 0,54 | |
| SupplierCustomer | 0,54 | -0,44 | -0,11 | -0,34 | -0,70 | -0,07 | |
| SupplierCustomer | 0,47 | 0,78 | 0,51 | 0,64 | 0,77 | 0,66 | |
| SupplierCustomer | 0,44 | -0,09 | 0,37 | 0,68 | 0,86 | 0,16 | |
| SupplierCustomer | -0,05 | 0,77 | 0,48 | 0,62 | 0,78 | 0,73 | |
| SupplierCustomer | -0,30 | 0,49 | 0,54 | -0,05 | 0,10 | -0,30 |
1
Most common questions regarding Chiome Bioscience
What is the P/S ratio of Chiome Bioscience 2025?
The P/S cannot be calculated for Chiome Bioscience currently.
What is the Quality Investing of Chiome Bioscience?
The Quality Investing for Chiome Bioscience is 4/10.
What is the revenue of Chiome Bioscience 2025?
The revenue cannot currently be calculated for Chiome Bioscience.
How high is the profit of Chiome Bioscience 2025?
The profit cannot currently be calculated for Chiome Bioscience.
What is the business model of Chiome Bioscience
No history available for Chiome Bioscience.
What is the Chiome Bioscience dividend?
Chiome Bioscience pays a dividend of 0 JPY distributed over payouts per year.
How often does Chiome Bioscience pay dividends?
The dividend cannot currently be calculated for Chiome Bioscience or the company does not pay out a dividend.
What is the Chiome Bioscience ISIN?
The ISIN of Chiome Bioscience is JP3205350006.
What is the Chiome Bioscience ticker?
The ticker of Chiome Bioscience is 4583.T.
How much dividend does Chiome Bioscience pay?
Over the past 12 months, Chiome Bioscience paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Chiome Bioscience is expected to pay a dividend of 0 JPY.
What is the dividend yield of Chiome Bioscience?
The current dividend yield of Chiome Bioscience is .
When does Chiome Bioscience pay dividends?
Chiome Bioscience pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Chiome Bioscience?
Chiome Bioscience paid dividends every year for the past 0 years.
What is the dividend of Chiome Bioscience?
For the upcoming 12 months, dividends amounting to 0 JPY are expected. This corresponds to a dividend yield of 0 %.
In which sector is Chiome Bioscience located?
Chiome Bioscience is assigned to the 'Health' sector.
Wann musste ich die Aktien von Chiome Bioscience kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Chiome Bioscience from 2/26/2025 amounting to 0 JPY, you needed to have the stock in your portfolio before the ex-date on 2/26/2025.
When did Chiome Bioscience pay the last dividend?
The last dividend was paid out on 2/26/2025.
What was the dividend of Chiome Bioscience in the year 2024?
In the year 2024, Chiome Bioscience distributed 0 JPY as dividends.
In which currency does Chiome Bioscience pay out the dividend?
The dividends of Chiome Bioscience are distributed in JPY.
Chiome Bioscience stock
Sector
Health
Industry
Life Sciences Tools & Services
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website Chiome Bioscience
Country
Japan 🇯🇵
Currency
JPY
Initial public offering
Dec 20, 2011
GOSIN
Global Open Securities Identification Number
Cusip
J0645U104
Market capitalization
Quality Investing
4 / 10Details
PEG
0
P/E ratio
Forward P/E ratio
0
P/S ratio
Forward P/S ratio
0
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
Chiome Bioscience Peer Group
Chiome Bioscience Eulerpool News
Chiome Bioscience News
Chiome Bioscience FIGI
| Chiome Bioscience Ticker | Chiome Bioscience FIGI |
|---|---|
| 4583:JP | BBG00283XKK7 |
| 4583:JT | BBG00283XKL6 |
| 4583:JJ | BBG00283XKW4 |
| 4583:JE | BBG00283XL07 |
| 4583:JI | BBG00283XL16 |
| 4583:JU | BBG002QKJK34 |
| 4583:JW | BBG00875LBJ5 |
| 4583:JV | BBG0193RCRL0 |
All fundamentals about Chiome Bioscience
Our stock analysis for Chiome Bioscience Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Chiome Bioscience Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
Chiome Bioscience Revenue- Chiome Bioscience Net Income
- Chiome Bioscience P/E
- Chiome Bioscience P/S
- Chiome Bioscience EBIT
- Chiome Bioscience Dividend
- Chiome Bioscience Stocks
- Chiome Bioscience Market capitalization
- Chiome Bioscience Debt
- Chiome Bioscience Liabilities
- Chiome Bioscience Equity
- Chiome Bioscience AAQS
- Chiome Bioscience Employees
- Chiome Bioscience ROE
- Chiome Bioscience ROA
- Chiome Bioscience ROCE